Rajat Garg

Rajat Garg

Auto-generated profile, based on publicly available information

Rajat Garg

Department of Gastroenterology University of Texas Health San Antonio Texas USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2018 in BioMed Research International
Verified
Journal Article
Open access
PDF file
RGRajat Garg
Rajat Garg
TRTarun Rustagi
Tarun Rustagi
Hypertriglyceridemia is an uncommon but a well-established etiology of acute pancreatitis leading to significant morbidity and mortality. The risk and severity of acute pancreatitis increase with increasing levels of serum triglycerides. It is crucial to identify hypertriglyceridemia as the cause of pancreatitis and initiate appropriate treatment plan. Initial supportive treatment is similar to management of other causes of acute pancreatitis with additional specific therapies tailored to lower serum triglycerides levels. This includes plasmapheresis, insulin, heparin infusion, and hemofiltration. After the acute episode, diet and lifestyle modifications along with hypolipidemic drugs should be initiated to prevent further episodes. Currently, there is paucity of studies directly comparing different modalities. This article provides a comprehensive review of management of hypertriglyceridemia induced acute pancreatitis. We conclude by summarizing our treatment approach to manage hypertriglyceridemia induced acute pancreatitis.

1 May 2022 in Endoscopic Ultrasound
Verified
Journal Article
Open access
RGRajat Garg
Rajat Garg
AMAbdul Mohammed
Abdul Mohammed
ASAmandeep Singh
Amandeep Singh
MHMary P. Harnegie
Mary P. Harnegie
TRTarun Rustagi
Tarun Rustagi
PCPrabhleen Chahal
Prabhleen Chahal
EUS-guided radiofrequency ablation (RFA) and ethanol ablation (EA) for pancreatic neuroendocrine tumors (PNETs) have recently been reported with good outcomes. We performed a systematic review and meta-analysis to evaluate the comparative effectiveness and safety of EUS-RFA and EUS-EA in the treatment of PNETs. A comprehensive search of multiple databases (through October 2020) was performed to identify studies that reported outcomes of EUS-RFA and EUS-EA of PNETs. Outcomes assessed included clinical success, technical success, and adverse events (AEs). A total of 181 (100 EUS-RFA, 81 EUS-EA) patients (60.7 ± 9.2 years) with 204 (113 EUS-RFA, 91 EUS-EA) PNETs (mean size 15.1 ± 4.7 mm) were included from 20 studies. There was no significant difference in the rates of technical success (94.4% [95% confidence interval (CI): 88.5–97.3, I 2 = 0] vs. 96.7% [95% CI: 90.8–98.8, I 2 = 0]; P = 0.42), clinical success (85.2% (95% CI: 75.9–91.4, I 2 = 0) vs. 82.2% [95% CI: 68.2–90.8, I 2 = 10.1]; P = 0.65), and AEs (14.1% [95% CI: 7.1–26.3, I 2 = 0] vs. 11.5% [95% CI: 4.7–25.4, I 2 = 63.5]; P = 0.7) between EUS-RFA and EUS-EA, respectively. The most common AE was pancreatitis with the rate of 7.8% and 7.6% (P = 0.95) for EUS-RFA and EUS-EA, respectively. On meta-regression, the location of PNETs in head/neck of pancreas (P = 0.03) was a positive predictor of clinical success for EUS-RFA. EUS-RFA and EUS-EA have similar effectiveness and safety for PNETs ablation. Head/neck location of PNETs was a positive predictor for clinical success after EUS-RFA.

10 June 2022 in Endoscopy International Open
Verified
Journal Article
Open access
PDF file
RGRajat Garg
Rajat Garg
AMAbdul Mohammed
Abdul Mohammed
ASAmandeep Singh
Amandeep Singh
MSMary Schleicher
Mary Schleicher
PTPrashanthi N. Thota
Prashanthi N. Thota
MSMadhusudhan R Sanaka
Madhusudhan R Sanaka
Background and study aims Anti-reflux mucosectomy (ARMS) is an emerging endoscopic treatment for refractory gastroesophageal reflux disease (GERD). We conducted a systematic review and meta-analysis to evaluate the safety and efficacy ARMS in refractory GERD. Methods A comprehensive search of multiple databases (through March 2020) was performed to identify studies that reported outcomes of ARMS for refractory GERD. Outcomes assessed included technical success, clinical response, and adverse events (AEs). Clinical response was defined as discontinuation (complete) or reduction (partial) of proton pump inhibitors post-ARMS at follow up. Results A total of 307 patients (mean age 46.9 [8.1] years, 41.5 % females) were included from 10 studies. The technical success and clinical response rates were 97.7 % (95 % confidence interval [CI], 94.6–99.0) and 80.1 % (95 % CI, 61.6–91.0), respectively. The pooled rate of complete and partial clinical response was 65.3 % (95 % CI, 51.4–77.0) and 21.5 % (95 % CI, 14.2–31.2), respectively. The rate of AEs was 17.2 % (95 % CI, 13.1–22.2) with most common AE being dysphagia/esophageal stricture followed by bleeding with rates of 11.4 % and 5.0 %, respectively. GERD health-related quality of life (GERD-HRQL) (mean difference [MD] = 14.9, P < 0.001), GERD questionnaire (GERD-Q) (MD = 4.85, P < 0.001) and mean acid exposure time (MD = 2.39, P = 0.01) decreased significantly post-ARMS as compared to pre-procedure. There was no difference in terms of clinical response and AEs between ARMS and ARMS with banding on subgroup analysis. Conclusions ARMS is a safe and effective procedure for treatment of refractory GERD with high rates of clinical response, acceptable safety profile and significant improvement in GERD-related quality of life. Prospective studies are needed to validate our findings. * Meeting presentations: An abstract of this manuscript was accepted for poster presentation at the American College of Gastroenterology, 2021. Received: 23 August 2021 Accepted after revision: 15 November 2021 Article published online: 10 June 2022 © 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

23 June 2020 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
RGRajat Garg
Rajat Garg
BMBabu P. Mohan
Babu P. Mohan
SPSuresh Ponnada
Suresh Ponnada
ASAmandeep Singh
Amandeep Singh
AAAli Aminian
Ali Aminian
BCBenjamin Click
Benjamin Click

23 June 2021 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
RGRajat Garg
Rajat Garg
MAManik Aggarwal
Manik Aggarwal
RBRobert S. Butler
Robert S. Butler
JAJean-Paul Achkar
Jean-Paul Achkar
BLBret Lashner
Bret Lashner
BCBenjamin Click
Benjamin Click

17 November 2020 in Endoscopy International Open
Verified
Journal Article
Open access
PDF file
RGRajat Garg
Rajat Garg
ASAmandeep Singh
Amandeep Singh
BMBabu P. Mohan
Babu P. Mohan
GMGautam Mankaney
Gautam Mankaney
MRMiguel Regueiro
Miguel Regueiro
PCPrabhleen Chahal
Prabhleen Chahal
Background and study aims Underwater endoscopic mucosal resection (UEMR) for colorectal polyps has been reported to have good outcomes in recent studies. We conducted a systematic review and meta-analysis comparing the effectiveness and safety of UEMR to conventional EMR (CEMR). Methods A comprehensive search of multiple databases (through May 2020) was performed to identify studies that reported outcome of UEMR and CEMR for colorectal lesions. Outcomes assessed included incomplete resection, rate of recurrence, en bloc resection, adverse events (AEs) for UEMR and CEMR. Results A total of 1,651 patients with 1,704 polyps were included from nine studies. There was a significantly lower rate of incomplete resection (odds ratio [OR]: 0.19 (95 % confidence interval (CI), 0.05–0.78, P = 0.02) and polyp recurrence (OR: 0.41, 95 % CI, 0.24–0.72, P = 0.002) after UEMR. Compared to CEMR, rates overall complications (relative risk [RR]: 0.66 (95 % CI, 0.48–0.90) (P = 0.008), and intra-procedural bleeding (RR: 0.59, 95 % CI, 0.41–0.84, P = 0.004) were significantly lower with UEMR. The recurrence rate was also lower for large non-pedunculated polyps ≥ 10 mm (OR 0.24, 95 % CI, 0.10–0.57, P = 0.001) and ≥ 20 mm (OR 0.14, 95 % CI, 0.02–0.72, P = 0.01). The rates of en bloc resection, delayed bleeding, perforation and post-polypectomy syndrome were similar in both groups (P > 0.05). Conclusions In this systematic review and meta-analysis, we found that UEMR is more effective and safer than CEMR with lower rates of recurrence and AEs. UEMR use should be encouraged over CEMR. Received: 24 June 2020 Accepted: 21 September 2020 Publication Date: 27 November 2020 (online) © 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany